GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Maturation of human natural killer (NK) cells as defined by accumulation of cell-surface expression of CD57 is associated with increased cytotoxic character and TNF and IFNγ production upon target-cell recognition. Notably, multiple studies point to a unique role for CD57+ NK cells in cancer immunosurveillance, yet there is scant information about how they mature. In this study, we show that pharmacologic inhibition of GSK3 kinase in peripheral blood NK cells expanded ex vivo with IL15 greatly enhances CD57 upregulation and late-stage maturation. GSK3 inhibition elevated the expression of several transcription factors associated with late-stage NK-cell maturation including T-BET, ZEB2, and BLIMP-1 without affecting viability or proliferation. When exposed to human cancer cells, NK cell expanded ex vivo in the presence of a GSK3 inhibitor exhibited significantly higher production of TNF and IFNγ, elevated natural cytotoxicity, and increased antibody-dependent cellular cytotoxicity. In an established mouse xenograft model of ovarian cancer, adoptive transfer of NK cells conditioned in the same way also displayed more robust and durable tumor control. Our findings show how GSK3 kinase inhibition can greatly enhance the mature character of NK cells most desired for effective cancer immunotherapy. Cancer Res; 77(20); 5664–75. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Control of Effector CD8 + T Cell Function by the Transcription Factor Eomesodermin
Pearce, E. L., Mullen, A. C., Martins, G. A., Krawczyk, C. M., Hutchins, A. S., Zediak, V. P., Banica, M., DiCioccio, C. B., Gross, D. A., Mao, C.-A., et al. (2003) · Science · doi:10.1126/science.1090148 · Cited by 1,014
Lopez-Vergès, S., Milush, J. M., Schwartz, B. S., Pando, M. J., Jarjoura, J., York, V. A., Houchins, J. P., Miller, S., Kang, S.-M., Norris, P. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110900108 · Cited by 822
Lopez-Vergès, S., Milush, J. M., Pandey, S., York, V. A., Arakawa-Hoyt, J., Pircher, H., Norris, P. J., Nixon, D. F., & Lanier, L. L. (2010) · Blood · doi:10.1182/blood-2010-04-282301 · Cited by 752
Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease
Nielsen, C. M., White, M. J., Goodier, M. R., & Riley, E. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00422 · Cited by 282
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Self-citationNK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
NK cell-based cancer immunotherapy: from basic biology to clinical development
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01014-w · Cited by 689
Immunometabolism and natural killer cell responses
O’Brien, K. L., & Finlay, D. K. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0139-2 · Cited by 435
Metadata
- Authors
- Cichocki, F., Valamehr, B., Bjordahl, R., Zhang, B., Rezner, B., Rogers, P., Gaidarova, S., Moreno, S., Tuininga, K., Dougherty, P., McCullar, V., Howard, P., Sarhan, D., Taras, E., Schlums, H., Abbot, S., Shoemaker, D., Bryceson, Y. T., Blazar, B. R., Wolchko, S., Cooley, S., & Miller, J. S.
- Venue
- Cancer Research
- Published
- 2017-10-15
- Volume
- 77
- Issue
- 20
- Pages
- 5664-5675
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2742755221
- Cited by
- 151
- References
- 5
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-0799
- The paper
- Cichocki, F., Valamehr, B., Bjordahl, R., Zhang, B., Rezner, B., Rogers, P., Gaidarova, S., Moreno, S., Tuininga, K., Dougherty, P., McCullar, V., Howard, P., Sarhan, D., Taras, E., Schlums, H., Abbot, S., Shoemaker, D., Bryceson, Y. T., Blazar, B. R., . . . Miller, J. S. (2017). GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-0799
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.